Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 1,410,000 shares, a decrease of 22.1% from the October 15th total of 1,810,000 shares. Based on an average daily trading volume, of 213,500 shares, the short-interest ratio is presently 6.6 days. Currently, 7.9% of the shares of the stock are short sold.
Mineralys Therapeutics Trading Up 12.4 %
MLYS opened at $7.15 on Wednesday. The company has a market cap of $293.87 million and a price-to-earnings ratio of -2.28. The stock has a fifty day simple moving average of $9.36 and a two-hundred day simple moving average of $12.79. Mineralys Therapeutics has a 12-month low of $6.14 and a 12-month high of $21.98.
Insider Transactions at Mineralys Therapeutics
In related news, CEO Jon Congleton bought 2,250 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was bought at an average cost of $12.10 per share, for a total transaction of $27,225.00. Following the completion of the transaction, the chief executive officer now owns 1,042,568 shares of the company’s stock, valued at $12,615,072.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Institutional Trading of Mineralys Therapeutics
Analysts Set New Price Targets
Separately, Credit Suisse Group reduced their price target on shares of Mineralys Therapeutics from $38.00 to $37.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Mineralys Therapeutics has an average rating of “Buy” and an average target price of $36.00.
Mineralys Therapeutics Company Profile
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.
- Five stocks we like better than Mineralys Therapeutics
- 3 Small Caps With Big Return Potential
- 5 must-have next-gen technologies that institutions are buying
- Business Services Stocks Investing
- 3 intriguing late-week earnings plays for short-term traders
- Learn Technical Analysis Skills to Master the Stock Market
- Datadog is about to hit 52-week highs, and there’s more to come
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.